-transparent.png){kind=logo}
A total of 134 patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone, 14 mg/m2 intravenously every 3 weeks. Of these, 99 could be evaluated for response and all for toxicity. Six patients achieved a complete response and 29 a partial response, the overall response rate being 35% (95% confidence limits 25% to 45%). The median time to treatment failure was greater than 46 weeks. Mitoxantrone was well tolerated. Nausea and vomiting occurred in 40% of patients, but these were seldom severe. Total alopecia occurred in only six patients. Four patients developed clinically significant evidence of cardiotoxicity after cumulative doses of 174 to 256 mg/m2. Mitoxantrone offers comparable efficacy and less acute toxicity than the most active single agents currently used in the treatment of advanced breast cancer.
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
August 1986,
Cancer treatment reports,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
January 1985,
Investigational new drugs,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
October 1987,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
March 1993,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
December 1983,
Cancer treatment reviews,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
January 1989,
Oncology,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
January 1985,
Investigational new drugs,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
January 1999,
Cancer control : journal of the Moffitt Cancer Center,
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
January 1993,
European journal of cancer (Oxford, England : 1990),
J F Smyth, and
M A Cornbleet, and
R C Stuart-Harris, and
I E Smith, and
R E Coleman, and
R D Rubens, and
M McDonald, and
H T Mouridsen, and
H Rainer, and
A T van Oosterom
January 1992,
Breast cancer research and treatment,
